標(biāo)題: Titlebook: Biomarkers for Immunotherapy of Cancer; Methods and Protocol Magdalena Thurin,Alessandra Cesano,Francesco M. Ma Book 2020 Springer Science+ [打印本頁] 作者: 時(shí)間 時(shí)間: 2025-3-21 19:11
書目名稱Biomarkers for Immunotherapy of Cancer影響因子(影響力)
書目名稱Biomarkers for Immunotherapy of Cancer影響因子(影響力)學(xué)科排名
書目名稱Biomarkers for Immunotherapy of Cancer網(wǎng)絡(luò)公開度
書目名稱Biomarkers for Immunotherapy of Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biomarkers for Immunotherapy of Cancer被引頻次
書目名稱Biomarkers for Immunotherapy of Cancer被引頻次學(xué)科排名
書目名稱Biomarkers for Immunotherapy of Cancer年度引用
書目名稱Biomarkers for Immunotherapy of Cancer年度引用學(xué)科排名
書目名稱Biomarkers for Immunotherapy of Cancer讀者反饋
書目名稱Biomarkers for Immunotherapy of Cancer讀者反饋學(xué)科排名
作者: 古董 時(shí)間: 2025-3-21 21:09 作者: 開始從未 時(shí)間: 2025-3-22 01:48
The CRISPR System and Cancer Immunotherapy Biomarkersedly speed up the development of new treatment options for cancer patients. The CRISPR system and its applications in biomedical research will be discussed with an emphasis on cancer immunotherapy and biomarker development.作者: 勉強(qiáng) 時(shí)間: 2025-3-22 06:40
Konflikte in modernen Gesellschaften (I),identifying germline biomarkers that disrupt miRNA circuitry, and then the selection, application, and validation of these biomarkers and their potential to predict important outcomes to checkpoint therapy.作者: 豪華 時(shí)間: 2025-3-22 12:42 作者: 不透氣 時(shí)間: 2025-3-22 15:27
1064-3745 ation advice from the experts.This book provides the immune oncology (IO) community with a deeper understanding of the scope of the biomarker methods to potentially improve the outcome from immunotherapy. The editors secured the input from experts in the field dedicated to translating scientific res作者: SPER 時(shí)間: 2025-3-22 17:07 作者: Abominate 時(shí)間: 2025-3-22 23:47 作者: 燒瓶 時(shí)間: 2025-3-23 02:27 作者: 元音 時(shí)間: 2025-3-23 08:20
https://doi.org/10.1007/978-3-658-04584-5 adding sophistication and accuracy to the investigations. Here, we summarize the history of functional genomic profiling as a discovery and validation tool for immune oncology (IO) and new insights that could be derived by single novel technologies.作者: 哥哥噴涌而出 時(shí)間: 2025-3-23 12:51 作者: 松緊帶 時(shí)間: 2025-3-23 17:01
Histone Modifications as Biomarkers for Immunotherapyive targets as biomarkers. We explore promising advancements for using histone PTMs as immunotherapy responsiveness biomarkers in both cancer and immune cells, and provide a methodological workflow for assaying histone PTMs in relevant samples.作者: tenuous 時(shí)間: 2025-3-23 20:46
Functional Genome Profiling to Understand Cancer Immune Responsiveness adding sophistication and accuracy to the investigations. Here, we summarize the history of functional genomic profiling as a discovery and validation tool for immune oncology (IO) and new insights that could be derived by single novel technologies.作者: 天文臺(tái) 時(shí)間: 2025-3-23 22:25 作者: 蒙太奇 時(shí)間: 2025-3-24 03:47
Methods in Molecular Biologyhttp://image.papertrans.cn/b/image/187799.jpg作者: ACRID 時(shí)間: 2025-3-24 10:35
Gruppenprozesse, -strukturen und -modelle,ment of clinically actionable biomarkers depends upon three features: (a) their biological role with respect to malignant transformation and tumor progression; (b) the ability to detect them with robust, reliable, and clinically applicable assays; and (c) their prognostic or predictive value, as val作者: 灰姑娘 時(shí)間: 2025-3-24 12:17
Empirische Modellbildung: Das MIPO-Modell,f-sustaining cells capable of untrammeled growth. Although multiple modalities including surgery, radiation, and chemotherapy are available for the treatment of cancer, the benefits conferred are often limited. The immune system is capable of specific, durable, and adaptable responses. However, canc作者: cocoon 時(shí)間: 2025-3-24 17:45
https://doi.org/10.1007/978-3-8350-5523-0d the immune checkpoint), is one of the most promising approaches for cancer treatment and the use of immune checkpoint inhibitors (ICI) has demonstrated remarkable success in several types of cancer. In studies of unselected patient populations, it was shown that melanoma, non small cell lung cance作者: xanthelasma 時(shí)間: 2025-3-24 20:02
https://doi.org/10.1007/978-3-8350-5523-0 the feasibility of noninvasive testing and the personalized potential of IO outcome prediction catered to individual patients. Growing evidence from experimental or population-based studies suggests that the host genetic factors contribute to the immunological status of a patient as it plays out at作者: orthodox 時(shí)間: 2025-3-25 00:35
Gruppenprozesse, -strukturen und -modelle, MSI-H+ has been detected in a variety of cancer types, in addition to the classical cancers associated with Lynch Syndrome. Clinical testing for MSI-H+ is currently performed primarily through traditional polymerase chain reaction (PCR) or immunohistochemistry (IHC) assays. However, next-generation作者: 不利 時(shí)間: 2025-3-25 05:12
https://doi.org/10.1007/978-3-476-99931-3tus could thus act as a predictive biomarker of responsiveness to immunotherapy with recent immune checkpoint inhibitors. Among several factors involved in determining the hypermutated status, such as inactivating mutations in the DNA polymerases as well as exposure to external (cigarette smoke, UV 作者: FOVEA 時(shí)間: 2025-3-25 10:20 作者: faultfinder 時(shí)間: 2025-3-25 15:26
https://doi.org/10.1007/978-3-476-99931-3age, where the survival rates drop from approximately 90% (detection at an early stage) to 20%. Furthermore, ovarian cancer is not associated with overt physical symptoms. Thus, there is an urgent need for a highly sensitive and minimally invasive biomarker for the early detection of ovarian cancer.作者: 愛好 時(shí)間: 2025-3-25 16:13 作者: Intrepid 時(shí)間: 2025-3-25 20:59
Rollen- und Planspiele in der Lehre, while others show little benefit or develop resistance. Identification of biomarkers to predict responsiveness will be helpful for informing treatment strategies; and would furthermore lead to the identification of molecular pathways dysregulated in nonresponding patients that could be targeted for作者: ENDOW 時(shí)間: 2025-3-26 01:43
https://doi.org/10.1007/978-3-658-04584-5responsiveness (CIR) by looking for predictors of response, understanding mechanisms of action (MOA) of therapeutics and documenting strategies adopted by tumor cells to escape immune recognition. This approach led to the first description in 2002 of predictors of CIR, the characterization of the ph作者: 表狀態(tài) 時(shí)間: 2025-3-26 07:13
https://doi.org/10.1007/978-3-658-04584-5nalytical methods to deconstruct the genomics data can then be applied to infer gene expression patterns associated with the presence of various immunocyte populations. High quality RNA-seq is possible from formalin-fixed, paraffin-embedded (FFPE), fresh-frozen, and fresh tissue, with a wide variety作者: Gingivitis 時(shí)間: 2025-3-26 10:13
Konflikte verstehen und steuernrategies such as genomic or proteomic characterization are not able to adequately measure the biology. One particular advantage of transcriptional biomarkers is the ease with which they can be measured in the clinical setting using robust platforms such as the NanoString nCounter system. The nCounte作者: BOGUS 時(shí)間: 2025-3-26 15:49
https://doi.org/10.1007/978-3-322-89794-7arious treatment options. The emergency of a new genome editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR) technology, revolutionized the biomedical research field. We envision application of the CRISPR technology in cancer research, diagnosis, and therapy will mark作者: Radiation 時(shí)間: 2025-3-26 20:37
https://doi.org/10.1007/978-1-4939-9773-2Immuno-Oncology; FISH/RNA ISH; CRISPR/Cas9; HLA/KIR matching; EliSPOT作者: OUTRE 時(shí)間: 2025-3-26 22:29
978-1-4939-9775-6Springer Science+Business Media, LLC, part of Springer Nature 2020作者: 廣告 時(shí)間: 2025-3-27 04:11
Biomarkers for Immunotherapy of Cancer978-1-4939-9773-2Series ISSN 1064-3745 Series E-ISSN 1940-6029 作者: OVERT 時(shí)間: 2025-3-27 06:27 作者: 串通 時(shí)間: 2025-3-27 10:55
Status of Immune Oncology: Challenges and Opportunitiesely)..This introductory chapter to this book focuses on scientific and technical aspects relevant to the identification and validation of predictive biomarkers for immunotherapy. We emphasize that methods should address both the biology of the tumor and the tumor microenvironment. Moreover, the iden作者: Platelet 時(shí)間: 2025-3-27 17:33 作者: debacle 時(shí)間: 2025-3-27 20:25 作者: Dorsal-Kyphosis 時(shí)間: 2025-3-27 22:53 作者: 圓柱 時(shí)間: 2025-3-28 03:44
Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing preparation and quality control (QC), and outline the bioinformatics steps necessary for sequence alignment, preprocessing, and MSI-H+ detection using the software tool MANTIS. This workflow is intended to facilitate more widespread usage and adaptation of NGS-powered MSI detection, which can be ev作者: MELON 時(shí)間: 2025-3-28 08:29
Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma In metastatic melanoma, however, obtaining a tissue sample for molecular diagnostics is not typically a major obstacle to patient care plans; rather predicting treatment outcomes and monitoring a patient’s disease course during therapy are considered the current priorities for this cancer type. In 作者: 破譯密碼 時(shí)間: 2025-3-28 12:43 作者: 吹牛需要藝術(shù) 時(shí)間: 2025-3-28 14:43
Using RNA Sequencing to Characterize the Tumor Microenvironmentrence, HLA inference, and viral transcript quantification. In this chapter, we will describe our workflow for RNA-seq from bulk tissue to evaluable data, including extraction of RNA, library preparation methods, sequencing of libraries, alignment and quality assurance of data, and initial downstream作者: aspersion 時(shí)間: 2025-3-28 18:44
Development of Gene Expression-Based Biomarkers on the nCounter? Platform for Immuno-Oncology Applic. as well as design and execution of the development program in a way that will maximize likelihood of future success. This chapter introduces transcriptional biomarkers and provides an overview of the design and development process that will lead to a locked diagnostic assay that is ready for valid作者: POINT 時(shí)間: 2025-3-28 23:59 作者: FORGO 時(shí)間: 2025-3-29 03:10
Empirische Modellbildung: Das MIPO-Modell,ity of patients and indications, highlighting the need for more effective and novel approaches. Preclinical and clinical studies with immune checkpoint blockade are exploring the therapeutic potential antibody-based therapy targeting multiple inhibitory receptors. In this chapter, we discuss the cur作者: Obligatory 時(shí)間: 2025-3-29 08:40 作者: 不真 時(shí)間: 2025-3-29 13:18
https://doi.org/10.1007/978-3-8350-5523-0his chapter, we review the rationale for exploring the germline genetic factors as novel biomarkers predictive of IO outcomes, including ICI efficacy, toxicity, or survival, and discuss the approaches for the identification of such germline genetic surrogates. Specifically, we focus on strategies fo作者: Hemiparesis 時(shí)間: 2025-3-29 17:59
Gruppenprozesse, -strukturen und -modelle, preparation and quality control (QC), and outline the bioinformatics steps necessary for sequence alignment, preprocessing, and MSI-H+ detection using the software tool MANTIS. This workflow is intended to facilitate more widespread usage and adaptation of NGS-powered MSI detection, which can be ev作者: Inertia 時(shí)間: 2025-3-29 21:46
https://doi.org/10.1007/978-3-476-99931-3 In metastatic melanoma, however, obtaining a tissue sample for molecular diagnostics is not typically a major obstacle to patient care plans; rather predicting treatment outcomes and monitoring a patient’s disease course during therapy are considered the current priorities for this cancer type. In 作者: Ferritin 時(shí)間: 2025-3-30 03:32 作者: 無表情 時(shí)間: 2025-3-30 04:36
https://doi.org/10.1007/978-3-658-04584-5rence, HLA inference, and viral transcript quantification. In this chapter, we will describe our workflow for RNA-seq from bulk tissue to evaluable data, including extraction of RNA, library preparation methods, sequencing of libraries, alignment and quality assurance of data, and initial downstream作者: sulcus 時(shí)間: 2025-3-30 09:34
Konflikte verstehen und steuern. as well as design and execution of the development program in a way that will maximize likelihood of future success. This chapter introduces transcriptional biomarkers and provides an overview of the design and development process that will lead to a locked diagnostic assay that is ready for valid作者: hieroglyphic 時(shí)間: 2025-3-30 13:40 作者: Angioplasty 時(shí)間: 2025-3-30 18:49
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptorsf-sustaining cells capable of untrammeled growth. Although multiple modalities including surgery, radiation, and chemotherapy are available for the treatment of cancer, the benefits conferred are often limited. The immune system is capable of specific, durable, and adaptable responses. However, canc
